



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2263070 C 2009/09/08

(11)(21) **2 263 070**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 1997/08/12
(87) Date publication PCT/PCT Publication Date: 1998/02/19
(45) Date de délivrance/Issue Date: 2009/09/08
(85) Entrée phase nationale/National Entry: 1999/02/09
(86) N° demande PCT/PCT Application No.: EP 1997/004376
(87) N° publication PCT/PCT Publication No.: 1998/006387
(30) Priorité/Priority: 1996/08/13 (GB9617001.4)

(51) Cl.Int./Int.Cl. *A61K 31/60* (2006.01),
A61K 31/167 (2006.01), *A61K 47/14* (2006.01),
A61K 9/00 (2006.01), *A61P 1/02* (2006.01)
(72) Inventeur/Inventor:
BUSER, THOMAS, CH
(73) Propriétaire/Owner:
TILLOTS PHARMA AG, CH
(74) Agent: SIM & MCBURNEY

(54) Titre : COMPOSITION A USAGE BUCCAL
(54) Title: ORAL COMPOSITION

(57) **Abrégé/Abstract:**

A topical spreadable composition comprising 5-aminosalicylic acid (5-ASA) as active and monoolein is provided for treatment ulcers, inflammation and lesions of the oral cavity. The composition is spread over and adheres to the lesion, and is preferably prepared in a water free state. Examples of indications that can be treated are oral Crohn's Disease, aphthous ulcers, orofacial granulomatosis, oral ulcers associated with Behet's disease and oral lichen planus.



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/60, 9/00, 47/14	A3	(11) International Publication Number: WO 98/06387 (43) International Publication Date: 19 February 1998 (19.02.98)
(21) International Application Number: PCT/EP97/04376 (22) International Filing Date: 12 August 1997 (12.08.97) (30) Priority Data: 9617001.4 13 August 1996 (13.08.96) GB (71) Applicant (for all designated States except US): TILLOTTS PHARMA AG [CH/CH]; Hauptstrasse 27, CH-4417 Ziefen (CH). (72) Inventor; and (75) Inventor/Applicant (for US only): BUSER, Thomas [CH/CH]; Hauptstrasse 27, CH-4417 Ziefen (CH). (74) Agent: McMUNN, Watson, P.; W.H. Beck, Greener & Co., 7 Stone Buildings, Lincoln's Inn, London WC2A 3SZ (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims</i> <i>and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 19 March 1998 (19.03.98)
(54) Title: ORAL COMPOSITION COMPRISING 5-AMINOSALICYLIC ACID (57) Abstract A topical spreadable composition comprising 5-aminosalicylic acid (5-ASA) as active and monoolein is provided for treatment ulcers, inflammation and lesions of the oral cavity. The composition is spread over and adheres to the lesion, and is preferably prepared in a water free state. Examples of indications that can be treated are oral Crohn's Disease, aphthous ulcers, orofacial granulomatosis, oral ulcers associated with Behet's disease and oral <i>lichen planus</i> .		

Oral Composition

This invention relates to a 5-aminosalicylic acid (5-ASA) composition for the treatment or prophylaxis of oral ulcerations, inflammation and lesions of the oral cavity, and in particular the use the glyceryl monooleate in the preparation of such compositions.

Oral ulceration (or mouth ulcers) can be very painful and the resulting lesions can be mild or severe. There are various preparations for the treatment of oral ulcerations. For example carbenoxolone sodium can be helpful in promoting healing of mild oral lesions, lozenges and oral pastes containing corticosteroids are used for treating aphthous non-specific ulcers, salicylates can be used in mild inflammatory and painful oral lesions, and benzydamine hydrochloride has a topical anti-inflammatory and analgesic effect and is used as a mouthwash or spray for oral ulcerations. A difficulty of treating oral ulcerations with preparations such as sprays, lozenges and mouthwash is that the active agent of the preparation is only transiently in contact with the ulcer. Even with gelatin based pastes, which have a protective effect for non-infected ulcers, it is difficult to keep them on the lesion for a prolonged period.

An example of a mucoprotectant is OrabaseTM which contains carmellose sodium, pectin and gelatin. This composition, however, has an uncomfortable gritty mouthfeel.

5-aminosalicylic acid (5-ASA) is a known compound and is currently used in the treatment of inflammatory bowel disease such as Crohn's disease and ulcerative colitis. For these indications, 5-ASA is administered rectally as an enema, or orally as a controlled release

capsule. EP-A-0 352 826 relates to the use of 5-ASA for dermatological disorders associated with therapy-resistant loss of epithelium, such as pyoderma gangrenosum, leg ulcers, mouth ulcers, decubitus, bullous dermatoses and
5 burns. In addition, 5-ASA is water sensitive and therefore it is desirable to formulate it in a substantially water free composition.

Topical 5-ASA in a gauze poultice has also been
10 reported as treating oral and genital lesions resulting from Behcet's disease (British J. Dermatol., 1989, 120:471-72).

The present invention is directed towards the
15 provision of an effective treatment for oral ulceration, inflammation and lesions of the oral cavity, in particular of the tongue, gingivae, lips, palate and buccal mucosa.

We have now surprisingly found an effective
20 medicament for treating oral ulcerations, inflammation, and lesions of the oral cavity which comprises 5-ASA as active agent or a physiologically acceptable derivative thereof, and glyceryl monooleate. The glyceryl monooleate is conveniently spread in a thin film over the ulcer and
25 forms an adhesive bond with the mucous of the ulcer, which in turn maintains the 5-ASA in contact with the ulcer for a prolonged period. Furthermore, we have found that the glyceryl monooleate can be used in a substantially water free state, which helps to stabilise the 5-ASA and prolong
30 the shelf life of the composition.

Preferably, monoolein (containing glyceryl monooleate) is used in the composition of the invention.

35 By monoolein we mean a product which consists predominantly of glyceryl monooleate, although various other glycerides of oleic acid and other fatty acids

could be present. Hereinafter references to glyceryl monooleate should be construed also as a reference to monoolein (CAS Registry No. 25496-72-4) and visa versa.

5 Preferably glyceryl monooleate (and monoolein) is formulated in a substantially water-free state. This enhances the shelf life of the composition.

10 Monoolein is a mixture of the glycerides of oleic acid and other fatty acids, consisting mainly of the glyceryl monooleate. A commercial form of monoolein is sold by Eastman Chemicals (e.g. at Hemel Hempstead, UK or Denver, USA) under the trade name MyverolTM. The manufacturers recommended uses of MyverolTM are: for
15 sustained release formulations, for topical permeation enhancement, for solubilisation of a water soluble drug into an oil matrix, and for sustained release microspheres. Monoolein is normally formulated in its fully hydrated cubic phase (which contains up to about
20 40% water) to produce its advantageous sustained release properties (J.Phy.Chem.1989, 93, 7304-7314 and EP-A-0 314 689).

 A composition comprising monoolein and an active
25 such as metronidazole (an antibacterial) is described in EP-A-0 671 175 and equivalent US-A-5 261 164 as a sustained release product for treating periodontal disease. The composition is injected into the periodontal pocket, preferably by a syringe. Such a
30 product is sold under the trade name ElyzolTM which is issued with a disposable applicator for the treatment of chronic periodontal disease. Similar periodontal type applications of monoolein are disclosed in Pharmaceutical Technology Europe Feb 1995, p14-16, and J.Clin.
35 Periodontal 1992; 19:687-692.

AMENDED SHEET

Accordingly in a first aspect of the present invention there is provided a spreadable mucoadhesive topical pharmaceutical composition comprising 5-ASA or a physiologically acceptable derivative thereof, glyceryl monooleate and white soft paraffin.

In a second aspect, there is provided the use of 5-ASA or a physiologically acceptable derivative thereof, glyceryl monooleate and white soft paraffin in the preparation of a spreadable medicament for the topical treatment of oral ulcerations, inflammation and lesions of the oral cavity.

In a third aspect, the invention provides the use of white soft paraffin to improve the spreadability of a mucoadhesive topical pharmaceutical composition comprising 5-ASA or a physiologically acceptable derivative thereof and glyceryl monooleate.

By physiologically acceptable derivative, we mean a derivative which is metabolised *in vivo*, such as by the enzymes in the oral cavity, to the same active metabolite as 5-ASA, and in particular includes physiologically acceptable salts and esters of 5-ASA.

An example of a derivative of 5-ASA is an N-acetyl derivative and its salts. Some esters have similar activity, e.g. alkyl esters, especially lower alkyl esters such as methyl, ethyl, propyl or isopropyl; alkenyl esters; cycloalkyl esters; aryl esters; alicyclic esters; and aralkyl esters.

Examples of physiologically acceptable salts of 5-ASA and its derivatives include salts derived from an appropriate base, such as an alkali metal (for example sodium or potassium), an alkaline earth metal (for

PCT/GB97/04376

-5-

example magnesium), ammonium or NX_4^+ , wherein X is a C_{1-4} alkyl group.

Most oral ulcerations or lesions should respond to treatment with a composition of the present invention particularly including the following: oral aphthous ulcers, oral mucositis (including mucositis neuroticans agranulocytica), oral Crohn's disease, ulcers in patients with ulcerative colitis, orofacial granulomatosis, denture stomatitis, oral ulcers associated with Behcet's Disease, oral lichen planus, pemphigus of the mouth, herpetic ulcers and traumatic lesions. By lesion we mean to include papule, nodule, weal, vesicle, bulla, plaque, scale, excoriation, scar, and lichenification.

15

Oral mucositis is an inflammation of the oral mucous surface and, for example, can result from chemotherapy.

Symptoms of oral Crohn's disease can include thickening of the mucous membranes of the mouth and lip.

20

Symptoms of orofacial granulomatosis can include furrowing of the tongue, thickening of the lower lip and buccal mucosa, and recurrent aphthous ulcers.

25

The composition of the invention is ideally suited for treating oral ulceration, inflammation and lesions of the tongue, palate, lips, gingivae and most preferably the buccal mucosa.

30

White soft paraffin wax is used to improve the rheological behaviour of glyceryl monooleate (i.e. improve its spreadability). Surprisingly, the white soft paraffin also helps prevent sedimentation of solids in the formulation as compared to other oils such as paraffin, glycerol, and arachis oil.

35

Optional components which can also be used in the composition include anaesthetic agents, flavourings, surfactants, penetration enhancers, antioxidants, polymers, opacifiers, and viscosity modifying agents
5 including hydrocarbon waxes and oils such as glycerol.

Other preferred optional components are titanium dioxide as an opacifier, lidocaine hydrochloride as an anaesthetic, benzyl alcohol as a penetration enhancer and
10 ascorbyl palmitate as an antioxidant. Ascorbyl palmitate is a particularly good antioxidant in a substantially water-free composition of the invention.

The amount of each component in a formulation can
15 vary. Thus 5-ASA could be used at up to 20% w/w, preferably 1% to 10% w/w, more preferably 3% to 7% w/w and most preferably about 5% w/w. Glyceryl monooleate (or monoolein) can be present at 10% to 99% w/w, preferably 20% to 80% w/w, more preferably 40% to 60% w/w
20 and most preferably about 50% w/w. White soft paraffin, is desirably used at 10% to 50% w/w, preferably 25% to 45% w/w, most preferably about 35% w/w. Where the total weight is less than 100% w/w, the formulation would be made up with other optional components. An anaesthetic
25 agent, such as lidocaine, is desirably used at 1% to 5% w/w, preferably about 3% w/w. An antioxidant such as ascorbyl palmitate is desirably used at 0.1 to 1% w/w, preferably 0.3% to 0.7% w/w, most preferably about 0.5% w/w. Typically the composition can be administered in a
30 5g or 10g tube.

A particularly preferred embodiment of the invention includes 5-ASA or a physiologically acceptable salt thereof, at 3% to 7% w/w, glyceryl monooleate at 40% to
35 60% w/w, white soft paraffin, at 25% to 45% w/w, anaesthetic, preferably lidocaine hydrochloride at 1% to

PCT/GB97/04376

- 7 -

5% w/w, ascorbyl palmitate at 0.1% to 1% w/w, preferably 0.3 to 0.7% and optional other components.

The composition of the invention is typically
5 supplied from a tube or pump dispenser and spread
topically using the finger tip in a smearing action over,
for example, the oral ulcer. In this way a thin
mucoadhesive film is formed which is comfortable and
convenient for the patient. In addition, the glyceryl
10 monooleate film protects the ulcer from further infection
and, because it is substantially insoluble in saliva, it
prevents the 5-ASA from being washed off the ulcer. As
such, with intermittent applications a therapeutically
effective amount of 5-ASA can be maintained in continuous
15 contact with the ulcerous lesion thereby accelerating
healing of the lesion. Typically a 5g tube of the
composition will contain about one hundred doses.

The invention will now be described by way of
20 example with reference to the following compositions.

Example 1

	<u>Active Constituent</u>	% w/w
	5-Aminosalicylic acid	5.0
25	<u>Other Constituents</u>	
	Myverol™ 18-99 (Monoglyceride)	53.5
	White Soft Paraffin	35.0
	Titanium Dioxide	5.0
30	Benzyl Alcohol	1.0
	Ascorbyl Palmitate	0.5
	Total:	100.0

35

AMENDED SHEET

Example 2

Example 1 was repeated, but without the addition of benzyl alcohol, and compensated for by increasing the weight of white soft paraffin.

Example 3

Example 1 was substantially repeated but lidocaine hydrochloride was additionally added as a local anaesthetic and benzyl alcohol omitted. The % w/w Myverol™ was decreased by a few units.

Example 4

Oral mucositis following chemotherapy is a common problem. 15 patients suffering from oral mucositis were asked to apply a 5-ASA/Myverol™ composition prepared in accordance with Example 1. All patients used chlorohexidine mouthwash and may have received benzydamine hydrochloride mouthwash and opioid analgesics. Each patient was asked to fill in a questionnaire at the end of a fifteen month study period. Of the 14 replies received, 2 patients were unable to recall details. Of the remaining 12 patients, 10 derived "overall" pain relief, 9 deriving relief on eating, 7 on drinking, and only 2 reported discomfort on application.

This study suggests that topical 5-ASA, particularly in a topical glyceryl monooleate composition, is of benefit in the management of chemoradiotherapy induced mucositis.

Example 5

A 14 year old boy with Crohn's Disease was asked to apply the composition in accordance with Example 1` twice

daily for six weeks. The oral Crohn's Disease produced a thickening of the mucous membranes in the mouth and lip and in this patient was associated with perianal disease. During the treatment there was also a clear improvement
5 inside the mouth, but very little difference to the lips.

Example 6

A 12 year old boy with Melkerson-Rosenthal syndrome
10 or orofacial granulomatosis had biopsies taken from his mouth which did not show granulomas diagnostic of Crohn's Disease. Otherwise the patient had symptoms identical to oral Crohn's Disease, but there was no evidence of a gut problem.

15

The patient's symptoms included thickening of the lower lip and buccal mucosa, furrowing of the tongue and recurrent aphthous ulceration. After one month applying a composition in accordance with the examples, the patient
20 was very pleased with his progress. Remarkably he developed only two ulcers during the treatment period.

-10-

The embodiments of the invention, in which an exclusive property or privilege is claimed, are defined as follows:

1. A substantially water-free spreadable mucoadhesive pharmaceutical composition for topical administration to a treatment location in the oral cavity, said composition comprising about 3% to about 7% w/w of a 5-aminosalicylic acid compound selected from 5-aminosalicylic acid and physiologically acceptable derivatives thereof, about 40% to about 60% w/w glyceryl monooleate, and about 25% to about 45% w/w white soft paraffin and being spreadable to form an adhesive film over the treatment location to maintain the 5-aminosalicylic acid compound in contact with the treatment location.
2. A composition as claimed in claim 1 comprising about 5% w/w 5-aminosalicylic acid or a physiologically acceptable derivative thereof, about 50% w/w glyceryl monooleate, and about 35% w/w white soft paraffin.
3. A composition as claimed in claim 1 or 2 further comprising one or more components selected from anaesthetic agents, flavourings, surfactants, penetration enhancers, antioxidants, polymers, and opacifiers.
4. A composition as claimed in claim 3 comprising at least one of 1% to 5% w/w anaesthetic agent and 0.1% to 1% w/w antioxidant.
5. The composition as claimed in claim 3 or claim 4 wherein the anaesthetic agent is a lidocaine anaesthetic agent and the antioxidant is ascorbyl palmitate.

-11-

6. A composition as claimed in any one of claims 1 to 5 wherein glyceryl monooleate is present as monoolein.

7. A substantially water-free pharmaceutical
5 formulation comprising about 3% to about 7% w/w of 5-aminosalicylic acid or physiologically acceptable derivatives thereof, about 40% to about 60% w/w glyceryl monooleate and about 25% to about 45% w/w white soft paraffin for use in the treatment of oral ulcerations,
10 inflammation, or lesions of the oral cavity.

8. The formulation of claim 7 formed into a film containing an effective amount of said 5-aminosalicylic acid compound selected from 5-aminosalicylic acid or
15 physiologically acceptable derivative thereof.

9. The formulation of claim 7 wherein said film is for use in spreading topically over the ulcer, lesion or inflamed mucosa.

20

10. The formulation as claimed in any one of claims 7 to 9 which comprise about 5% w/w 5-aminosalicylic acid, about 50% w/w glyceryl monooleate, and about 35% w/w white soft paraffin.